MiHKAL
 | |
| Industry | Pharmaceutical; Psychedelic medicine |
|---|---|
| Founded | 2021 in Basel, Switzerland |
| Founder | Matthias Grill |
| Headquarters | , |
| Website | www |
MiHKAL GmbH, with MiHKAL being an acronym of Molecules I Have Known and Loved, is a Swiss pharmaceutical company that is developing psychedelics and entactogens as potential medicines.[1][2] Matthias Grill is the founder and chief executive officer (CEO) of the company, while Tamara Hell is its co-founder and chief financial officer (CFO).[1][2] The name of the company is a play on the name of psychedelic chemist Alexander Shulgin's books PiHKAL (Phenethylamines I Have Known and Loved) and TiHKAL (Tryptamines I Have Known and Loved).[1][2]
MiHKAL has filed and published patents on prodrugs of psychedelics and/or entactogens.[2][3][4][5] In September 2021, Compass Pathways acquired MiHKAL's intellectual property (IP) and entered a non-exclusive partnership with the company to develop novel psychedelic compounds.[1][2][3][6][7][8] MiHKAL's drugs include lys-MDA and lys-MDMA, among others.[9][10][4][5]
The company MiHKAL should not be confused with the deceased psychedelic music artist of the name MiHKAL (standing for Music I Have Known and Loved; real name Michael Anderson).[11][12][13]
See also
[edit]References
[edit]- ^ a b c d "Psychedelic Stocks & Companies". Psychedelic Alpha. 8 November 2021. Retrieved 24 April 2025.
MiHKAL GmbH Founded by Dr. Matthias Grill, MiHKAL GmbH (as you might have guessed, the name is a play on Shulgin's TiHKAL and PiHKAL, with the 'M' in this case being 'Molecules') is a private contract research organization developing novel psychedelic drug candidates. The Swiss company has entered a non-exclusive research partnership with Compass Pathways to develop novel compounds.
- ^ a b c d e "Psychedelic Sector Overview". Psychedelic Alpha. 8 November 2021. Retrieved 24 April 2025.
MiHKAL GmbH Founded by Dr. Matthias Grill, MiHKAL GmbH (name derives from "Molecules I have known and loved") is a private contract research organization working to develop and patent novel psychedelic drug candidates. Located in Basel - Switzerland, the company is focused on research of new psychoactive compounds as well as on the synthesis of pharma-grade psychedelics. After having created several patents about prodrugs of known psychedelics, the company recently entered into a research agreement with Compass Pathways. The two companies will work together to expand Compass's proprietary drug development pipeline through the addition of novel compounds.
- ^ a b "Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics". Psychedelic Alpha. 17 September 2021. Retrieved 24 April 2025.
Earlier this week, COMPASS Pathways announced that it has acquired an IP portfolio that seeks to cover a "variety of psychedelic and empathogenic substances, some of which are prodrugs." The company says that the IP was developed with Matthias Grill PhD, via his company MiHKAL (presumably meaning Molecules I Have Known and Loved, in a nod to Shulgin's seminal publications), which is based in Basel, Switzerland: a short distance from the University of Basel where MindMed collaborator Dr. Matthias Liechti's lab is located.
- ^ a b "Novel safrylamine derivatives having prodrug properties". Google Patents. 13 September 2021. Retrieved 24 April 2025.
- ^ a b WO 2024/121253, Buchner M, "Novel N,N-Dimethyltryptamine (DMT) derivatives and uses thereof.", published 13 June 2024, assigned to Mihkal GmbH
- ^ "Psychedelic Company Highlights in 2021". Psychedelic Alpha. 20 January 2022. Retrieved 24 April 2025.
COMPASS Pathways Acquires MiHKAL GmbH, a Portfolio of Novel Psychedelic Compounds (September 14, 2021) In September, COMPASS Pathways announced that it had entered into an agreement with Matthias Grill Ph.D. and MiHKAL GmbH to acquire MiHKAL's catalogue of purportedly novel psychedelic and empathogenic compounds. In addition to the IP acquisition, COMPASS and Matthias Grill will continue to work together in an effort to develop new psychedelic drug candidates.
- ^ Ponieman, Natan (15 September 2021). "Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0". markets.businessinsider.com. Retrieved 24 April 2025.
The IP purchased was developed together with inventor Dr. Matthias Grill, founder and CEO of MiHKAL GmbH in Basel, Switzerland, who will be working with Compass on a research project to develop new product candidates.
- ^ "Research programme: psychedelic and empathogenic therapeutics - COMPASS Pathways - AdisInsight". adisinsight.springer.com.
- ^ Mind Medicine (MindMed) (20 September 2022). "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". PR Newswire. Retrieved 13 November 2024.
- ^ "Effects of MDMA-like Substances in Healthy Subjects (MDMA-like)". ClinicalTrials.gov. Retrieved 13 November 2024.
- ^ Anand Harsh (24 February 2020). "MiM0SA releases open letter to fans, sits down for an honest interview".
In an industry rocked by the deaths of young stars such as Mac Miller, Avicii, Juice Wrld, Lil Peep, as well as his friends and fellow luminaries in the underground bass scene Sleepyhead and MiHKAL, [...] I lost two of my best friends in 2019, Michael Anderson [MiHKAL] and Samuel Pohner, [...]
- ^ "Medicine Ball Party – Multidisciplinary Association for Psychedelic Studies – MAPS". Multidisciplinary Association for Psychedelic Studies – MAPS – Psychedelic Research for Psychological Healing. 10 August 2011. Retrieved 24 April 2025.
- ^ "MiHKAL". SoundCloud. 9 July 2019. Retrieved 24 April 2025.